Extending the new era of genomic testing into pregnancy management: A proposed model for Australian prenatal services

• Published in: Australian & New Zealand journal of obstetrics & gynaecology 2024-10, Vol.64 (5), p.467-474
• Main Authors: Rogers, Alice, De Jong, Lucas, Waters, Wendy, Rawlings, Lesley H., Simons, Keryn, Gao, Song, Soubrier, Julien, Kenyon, Rosalie, Lin, Ming, King, Rob, Lawrence, David M., Muller, Peter, Leblanc, Shannon, McGregor, Lesley, Sallevelt, Suzanne C. E. H., Liebelt, Jan, Hardy, Tristan S. E., Fletcher, Janice M., Scott, Hamish S., Kulkarni, Abhi, Barnett, Christopher P., Kassahn, Karin S.
• Format: Article
• Language: English
• Subjects: Adult; Australia; congenital abnormalities; exome; Exome Sequencing; Female; Genetic Testing; genomics; Gestational Age; Humans; Original; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Prenatal Care; Prenatal Diagnosis; Prospective Studies; rapid
• ISSN: 0004-8666; 1479-828X; 1479-828X
• DOI: 10.1111/ajo.13814

Background Trio exome sequencing can be used to investigate congenital abnormalities identified on pregnancy ultrasound, but its use in an Australian context has not been assessed. Aims Assess clinical outcomes and changes in management after expedited genomic testing in the prenatal period to guide the development of a model for widespread implementation. Materials and methods Forty‐three prospective referrals for whole exome sequencing, including 40 trios (parents and pregnancy), two singletons and one duo were assessed in a tertiary hospital setting with access to a state‐wide pathology laboratory. Diagnostic yield, turn‐around time (TAT), gestational age at reporting, pregnancy outcome, change in management and future pregnancy status were assessed for each family. Results A clinically significant genomic diagnosis was made in 15/43 pregnancies (35%), with an average TAT of 12 days. Gestational age at time of report ranged from 16 + 5 to 31 + 6 weeks (median 21 + 3 weeks). Molecular diagnoses included neuromuscular and skeletal disorders, RASopathies and a range of other rare Mendelian disorders. The majority of families actively used the results in pregnancy decision making as well as in management of future pregnancies. Conclusions Rapid second trimester prenatal genomic testing can be successfully delivered to investigate structural abnormalities in pregnancy, providing crucial guidance for current and future pregnancy management. The time‐sensitive nature of this testing requires close laboratory and clinical collaboration to ensure appropriate referral and result communication. We found the establishment of a prenatal coordinator role and dedicated reporting team to be important facilitators. We propose this as a model for genomic testing in other prenatal services.